Epizyme Inc (NASDAQ:EPZM) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.07. Epizyme had a negative net margin of 1,205.01% and a negative return on equity of 41.56%.
Epizyme (NASDAQ:EPZM) traded up 6.73% on Friday, hitting $18.25. 287,047 shares of the stock traded hands. The company’s 50 day moving average price is $16.04 and its 200-day moving average price is $13.24. The stock’s market capitalization is $1.07 billion. Epizyme has a 12-month low of $7.02 and a 12-month high of $18.50.
COPYRIGHT VIOLATION WARNING: This piece was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/05/19/epizyme-inc-epzm-releases-earnings-results-beats-expectations-by-0-07-eps-updated.html.
A number of research firms have commented on EPZM. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Tuesday. Cann restated an “outperform” rating and set a $26.00 price target on shares of Epizyme in a research report on Wednesday, April 12th. Wedbush reiterated an “outperform” rating and issued a $24.00 target price on shares of Epizyme in a report on Thursday. Royal Bank of Canada reiterated an “outperform” rating and issued a $20.00 target price (up from $19.00) on shares of Epizyme in a report on Wednesday, May 10th. Finally, CIBC reiterated an “outperform” rating on shares of Epizyme in a report on Thursday, April 13th. Eleven research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $24.88.
In related news, CFO Andrew E. Singer sold 2,013 shares of the firm’s stock in a transaction dated Friday, March 31st. The stock was sold at an average price of $17.09, for a total transaction of $34,402.17. Following the transaction, the chief financial officer now directly owns 36,175 shares of the company’s stock, valued at approximately $618,230.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Robert A. Copeland sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 2nd. The stock was sold at an average price of $17.44, for a total value of $87,200.00. Following the transaction, the insider now owns 36,538 shares in the company, valued at $637,222.72. The disclosure for this sale can be found here. Insiders have sold a total of 12,013 shares of company stock worth $203,402 in the last three months. 25.40% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in EPZM. Legal & General Group Plc boosted its position in shares of Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares during the last quarter. UBS Asset Management Americas Inc. bought a new position in shares of Epizyme during the first quarter worth about $175,000. Bank of America Corp DE boosted its position in shares of Epizyme by 45.4% in the first quarter. Bank of America Corp DE now owns 14,561 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 4,544 shares during the last quarter. American International Group Inc. boosted its position in shares of Epizyme by 7.1% in the first quarter. American International Group Inc. now owns 24,779 shares of the biopharmaceutical company’s stock worth $425,000 after buying an additional 1,638 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new position in shares of Epizyme during the fourth quarter worth about $351,000. Institutional investors and hedge funds own 79.98% of the company’s stock.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc and related companies with MarketBeat.com's FREE daily email newsletter.